Nanovibronix Inc
NAOV0.856USD
+0.031+3.77%
Market hours （ET）Quotes delayed by 15 min
628.40KMarket Cap
LossP/E TTM
More Details of Nanovibronix Inc Company
NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
Company Info
Ticker SymbolNAOV
Company nameNanovibronix Inc
IPO dateApr 24, 2015
CEODr. Doron Besser, M.D.
Number of employees15
Security typeOrdinary Share
Fiscal year-endApr 24
Address969 Pruitt Piace
CityTYLER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code75703
Phone19142333004
Websitehttps://nanovibronix.com/
Ticker SymbolNAOV
IPO dateApr 24, 2015
CEODr. Doron Besser, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Director
Director
--
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Director
Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
986.00K
96.20%
New Zealand
19.00K
1.85%
Other
11.00K
1.07%
Europe
9.00K
0.88%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
3.19%
Armistice Capital LLC
1.54%
Morgan Stanley & Co. LLC
0.53%
UBS Financial Services, Inc.
0.20%
Tower Research Capital LLC
0.04%
Other
94.50%
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
3.19%
Armistice Capital LLC
1.54%
Morgan Stanley & Co. LLC
0.53%
UBS Financial Services, Inc.
0.20%
Tower Research Capital LLC
0.04%
Other
94.50%
Shareholder Types
Shareholders
Proportion
Holding Company
3.19%
Hedge Fund
1.58%
Research Firm
0.53%
Investment Advisor
0.20%
Individual Investor
0.03%
Other
94.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
2023Q1
41
69.83K
4.25%
-82.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Capital Aktiengesellschaft
82.47K
3.19%
+49.29K
+148.54%
May 16, 2025
Armistice Capital LLC
39.88K
1.54%
+39.88K
--
Mar 31, 2025
Morgan Stanley & Co. LLC
13.62K
0.53%
+13.62K
--
Mar 31, 2025
UBS Financial Services, Inc.
5.16K
0.2%
+1.41K
+37.64%
Mar 31, 2025
Tower Research Capital LLC
1.01K
0.04%
+465.00
+84.55%
Mar 31, 2025
Fashek (Christopher M)
341.00
0.01%
--
--
May 16, 2025
Northern Trust Investments, Inc.
102.00
0%
+102.00
--
Dec 31, 2023
Brown (Stephen Russell)
18.00
0%
--
--
May 16, 2025
Cassirer (Aurora)
9.00
0%
--
--
Mar 31, 2025
BofA Global Research (US)
7.00
0%
+4.00
+133.33%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Date
Type
Ratio
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
